Medicine & Life Sciences
Acute Myeloid Leukemia
100%
Survival
71%
Therapeutics
53%
Drug Therapy
53%
Neoplasms
52%
Randomized Controlled Trials
52%
Breast Neoplasms
52%
Stem Cell Transplantation
52%
Allogeneic Cells
50%
Recurrence
50%
Urinary Bladder Neoplasms
41%
Leukemia
39%
Clinical Trials
36%
Transplants
35%
Systematic Reviews
32%
Meta-Analysis
30%
Hepatocellular Carcinoma
30%
Child
28%
T-Lymphocytes
28%
Biomarkers
27%
Radiotherapy
25%
Transplantation
25%
Bone Marrow
25%
Confidence Intervals
24%
Unrelated Donors
24%
Tissue Donors
23%
Pediatrics
22%
Placebos
22%
exemestane
22%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
22%
Graft vs Host Disease
21%
Tamoxifen
21%
Human Herpesvirus 4
21%
Progression-Free Survival
20%
Biomedical Research
20%
Prostatic Neoplasms
18%
Safety
18%
Quality of Life
18%
Pancreatic Neoplasms
18%
Mortality
17%
Azacitidine
17%
Cost-Benefit Analysis
16%
Stem Cells
16%
Alemtuzumab
16%
Random Allocation
16%
Hematopoietic Stem Cell Transplantation
15%
Cisplatin
15%
Cytarabine
15%
Disease-Free Survival
15%
Cytogenetics
14%
Parkinson Disease
14%
B-Cell Chronic Lymphocytic Leukemia
13%
Multiple Myeloma
13%
Incidence
13%
Pharmaceutical Preparations
13%
Blood Platelets
12%
Myelodysplastic Syndromes
12%
PCI 32765
12%
Nasopharyngeal Carcinoma
12%
Siblings
12%
gemcitabine
12%
Mutation
11%
Fluorouracil
11%
Adjuvant Chemotherapy
11%
Population
11%
Strontium-89
11%
Renal Cell Carcinoma
11%
Non-Small Cell Lung Carcinoma
10%
Costs and Cost Analysis
10%
Cohort Studies
10%
Cyclophosphamide
10%
Allografts
10%
DNA
10%
Colorectal Neoplasms
10%
Hodgkin Disease
10%
Docetaxel
10%
Hormones
10%
Bayes Theorem
10%
Serum
10%
Proteins
10%
Health Care Outcome Assessment
10%
Prospective Studies
10%
Central Nervous System Neoplasms
10%
Out-of-Hospital Cardiac Arrest
10%
Hepatitis B virus
10%
Genes
9%
Appointments and Schedules
9%
Sample Size
9%
Pseudotumor Cerebri
9%
Chemoradiotherapy
9%
Rituximab
9%
Essential Thrombocythemia
9%
Phase II Clinical Trials
9%
Epinephrine
9%
Epirubicin
9%
Zoledronic Acid
8%
Melphalan
8%
Melanoma
8%
fludarabine
8%
Sorafenib
8%